Injective CEO Eric Chen expects US INJ ETFs to launch sooner than 2027

What happened

The CEO of Injective, Eric Chen, expects United States exchange-traded funds tied to the INJ token to launch sooner than 2027, according to the article. Two INJ-related ETF applications exist: the 21Shares Injective ETF and the Canary Staked INJ ETF.

Confirmed

Global impact / market context

A US ETF would let ordinary investors buy INJ through a stock brokerage account instead of a crypto exchange, possibly widening the buyer pool. Approval could also push INJ into mainstream portfolios, but the two named applications may face regulatory delays or rejection.

Analyst inference

INJ is the token of the Injective network, and it is watched alongside other DeFi assets. ETF filings are early steps, not guarantees, so the launch timing stated by the CEO is a company expectation, not a regulatory decision or a confirmed approval date for either fund.

Analyst inference

What to watch

1. Watch for formal progress on the two applications, the 21Shares Injective ETF and the Canary Staked INJ ETF, which are the only INJ-tied funds named in the article. Confirmed
2. Track whether the US securities regulator approves, delays, or rejects these INJ ETF applications, since any official decision would change the expected launch timeline described by Injective's CEO. Proposed
3. Monitor INJ token trading activity and DeFi sector flows, because investor positioning could shift if launch expectations rise or fall before any formal regulatory ruling appears. Analyst inference

Affected assets

• DEFI — DeFi
• INJ — Injective

Evidence

• theblock.co